Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson’s Disease?
暂无分享,去创建一个
V. Labrie | P. Brundin | L. Brundin | Peipei Li | Keerthi Thirtamara-Rajamani | M. L. Escobar Galvis | M. E. Escobar Galvis | Martha L. Escobar Galvis
[1] Manoj Kumar,et al. INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.
[2] T. Postmus. Genetics of Parkinson's disease , 2018 .
[3] B. Pakkenberg,et al. Cytokine profiling in the prefrontal cortex of Parkinson's Disease and Multiple System Atrophy patients , 2017, Neurobiology of Disease.
[4] M. Nalls,et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.
[5] V. Labrie,et al. Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection , 2017, Journal of Innate Immunity.
[6] M. Herrero,et al. Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease , 2017, Progress in Neurobiology.
[7] M. Tansey,et al. Microglial phenotypes in Parkinson’s disease and animal models of the disease , 2017, Progress in Neurobiology.
[8] Nicholas W Wood,et al. Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases , 2017, JAMA neurology.
[9] G. Wong,et al. A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity , 2017, Journal of Innate Immunity.
[10] B. Barres,et al. Reactive Astrocytes: Production, Function, and Therapeutic Potential. , 2017, Immunity.
[11] L. Parsons,et al. Central Nervous System Infection with Borna Disease Virus Causes Kynurenine Pathway Dysregulation and Neurotoxic Quinolinic Acid Production , 2017, Journal of Virology.
[12] Z. Qin,et al. Microglia activation contributes to quinolinic acid-induced neuronal excitotoxicity through TNF-α , 2017, Apoptosis.
[13] M. Goedert,et al. The Synucleinopathies: Twenty Years On , 2017, Journal of Parkinson's disease.
[14] Bruce V. Taylor,et al. Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression , 2017, Scientific Reports.
[15] M. Tansey,et al. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? , 2017, npj Parkinson's Disease.
[16] C. Tasca,et al. In vitro 6-hydroxydopamine-induced toxicity in striatal, cerebrocortical and hippocampal slices is attenuated by atorvastatin and MK-801. , 2016, Toxicology in vitro : an international journal published in association with BIBRA.
[17] Justine W. Debelius,et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease , 2016, Cell.
[18] R. MasseyAaron,et al. Alpha-Synuclein, a Novel Viral Restriction Factor Hiding in Plain Sight , 2016 .
[19] Seong-Cheol Park,et al. Functional characterization of alpha-synuclein protein with antimicrobial activity. , 2016, Biochemical and biophysical research communications.
[20] D. Hernandez,et al. Genome-wide assessment of Parkinson's disease in a Southern Spanish population , 2016, Neurobiology of Aging.
[21] D. Fuchs,et al. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation , 2016, Translational psychiatry.
[22] Simon G. Coetzee,et al. Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson’s disease etiology , 2016, Scientific Reports.
[23] Sarah A. Gagliano,et al. Genomics implicates adaptive and innate immunity in Alzheimer's and Parkinson's diseases , 2016, bioRxiv.
[24] C. Muo,et al. Hepatitis C virus infection as a risk factor for Parkinson disease , 2016, Neurology.
[25] P. Svenningsson,et al. Overexpression of α-synuclein simultaneously increases glutamate NMDA receptor phosphorylation and reduces glucocerebrosidase activity , 2016, Neuroscience Letters.
[26] A. Massey,et al. Alpha-Synuclein Expression Restricts RNA Viral Infections in the Brain , 2015, Journal of Virology.
[27] Huadong Zhou,et al. The association between infectious burden and Parkinson's disease: A case-control study. , 2015, Parkinsonism & related disorders.
[28] Juan Hong,et al. Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons , 2015, Cell Death and Disease.
[29] K. Jellinger. Neuropathobiology of non-motor symptoms in Parkinson disease , 2015, Journal of Neural Transmission.
[30] L. Huo,et al. Human α‐amino‐β‐carboxymuconate‐ε‐semialdehyde decarboxylase (ACMSD): A structural and mechanistic unveiling , 2015, Proteins.
[31] Jia-Yi Li,et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats , 2014, Acta Neuropathologica.
[32] Chuong B. Do,et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.
[33] L. Huo,et al. Human alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase (ACMSD): A structural and mechanistic unveiling. , 2014 .
[34] J. Bol,et al. Increased Amoeboid Microglial Density in the Olfactory Bulb of Parkinson's and Alzheimer's Patients , 2014, Brain pathology.
[35] Sara Hall,et al. Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment , 2013, Brain, Behavior, and Immunity.
[36] Vladimir Makarov,et al. The ACMSD gene, involved in tryptophan metabolism, is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism , 2013, Journal of Molecular Medicine.
[37] E. Dietrichs,et al. Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease , 2013, Neurobiology of Aging.
[38] O. Hwang. Role of Oxidative Stress in Parkinson's Disease , 2013, Experimental neurobiology.
[39] F. Blandini. Neural and Immune Mechanisms in the Pathogenesis of Parkinson’s Disease , 2013, Journal of Neuroimmune Pharmacology.
[40] Y. Surova,et al. Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum , 2012, PLoS ONE.
[41] J. Ioannidis,et al. Large-scale replication and heterogeneity in Parkinson disease genetic loci , 2012, Neurology.
[42] R. Schwarcz,et al. Kynurenines in the mammalian brain: when physiology meets pathology , 2012, Nature Reviews Neuroscience.
[43] M. Britschgi,et al. Inflammation and α-Synuclein’s Prion-like Behavior in Parkinson's Disease—Is There a Link? , 2012, Molecular Neurobiology.
[44] Chuong B. Do,et al. Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database , 2012, PLoS genetics.
[45] G A Perkins,et al. A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics , 2011, Cell Death and Disease.
[46] B. Brew,et al. Characterization of the kynurenine pathway in NSC‐34 cell line: implications for amyotrophic lateral sclerosis , 2011, Journal of neurochemistry.
[47] R. Schwarcz,et al. The Kynurenine Pathway Modulates Neurodegeneration in a Drosophila Model of Huntington's Disease , 2011, Current Biology.
[48] M. Herrero,et al. The Involvement of Neuroinflammation and Kynurenine Pathway in Parkinson's Disease , 2011, Parkinson's disease.
[49] P. Blain,et al. Mitochondrial Dysfunction in Parkinson's Disease , 2011, Parkinson's disease.
[50] J. Pedraza-Chaverri,et al. Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. , 2011, Neurotoxicology and teratology.
[51] Miguel Ángel Martínez,et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.
[52] D. Jane,et al. Functional heterogeneity of NMDA receptors in rat substantia nigra pars compacta and reticulata neurones , 2010, The European journal of neuroscience.
[53] F. Blandini. An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. , 2010, Functional neurology.
[54] J. Auwerx,et al. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. , 2010, Endocrine reviews.
[55] M. Goldberg,et al. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention , 2010, Neurobiology of Disease.
[56] Jing Zhang,et al. Glutamate, excitotoxicity, and programmed cell death in parkinson disease , 2009, Experimental Neurology.
[57] M. Holtze,et al. Induction of the kynurenine pathway by neurotropic influenza a virus infection , 2008, Journal of neuroscience research.
[58] L. Raymond,et al. N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease , 2007, Progress in Neurobiology.
[59] F. Cimadamore,et al. Tissue expression and biochemical characterization of human 2‐amino 3‐carboxymuconate 6‐semialdehyde decarboxylase, a key enzyme in tryptophan catabolism , 2007, The FEBS journal.
[60] P. Ligam,et al. Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: implications for role of the kynurenine pathway in pregnancy. , 2005, Placenta.
[61] Makoto Sawada,et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains , 2003, Acta Neuropathologica.
[62] Y. Egashira,et al. Identification and expression of alpha cDNA encoding human 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD): a key enzyme for the tryptophan-niacine pathway and quinolinate hypothesis. , 2002, Advances in experimental medicine and biology.
[63] Y. Egashira,et al. Expression of rat hepatic 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase is affected by a high protein diet and by streptozotocin-induced diabetes. , 2002, The Journal of nutrition.
[64] D. Souza,et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes , 2002, Neurochemistry International.
[65] T. Jernigan,et al. Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. , 2001, Brain : a journal of neurology.
[66] A. Graybiel,et al. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.
[67] A. Graybiel,et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.
[68] C. Colton,et al. Activated human microglia produce the excitotoxin quinolinic acid , 1997, Neuroreport.
[69] D. German,et al. Midbrain dopaminergic neurons in the mouse: co-localization with Calbindin-D28k and calretinin , 1996, Neuroscience.
[70] J. Rossier,et al. THE ENDOGENEOUS AGONIST QUINOLINIC ACID AND THE NON ENDOGENOUS HOMOQUINOLINIC ACID DISCRIMINATE BETWEEN NMDAR2 RECEPTOR SUBUNITS , 1996, Neurochemistry International.
[71] A. Wenzel,et al. Distribution of NMDA receptor subunit proteins NR2A, 2B, 2C and 2D in rat brain , 1995, Neuroreport.
[72] L. Meltzer,et al. Evidence for N-methyl-d-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: Possible preferential role for N-methyl-d-aspartate receptors , 1995, Neuroscience.
[73] R. Beninger,et al. Picolinic acid protects against quinolinic acid-induced depletion of NADPH diaphorase containing neurons in the rat striatum , 1994, Brain Research.
[74] R. Beninger,et al. Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: Evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry , 1994, Neuroscience.
[75] B. Sakmann,et al. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors , 1994, Neuron.
[76] R. Schwarcz,et al. Increased Brain Quinolinic Acid Production in Mice Infected with a Hamster Neurotropic Measles Virus , 1994, Experimental Neurology.
[77] Minoru Harada,et al. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.
[78] M. Beal,et al. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice , 1993, Neuroreport.
[79] T. Stone,et al. NMDA receptors and ligands in the vertebrate CNS , 1988, Progress in Neurobiology.
[80] T. Williams,et al. Amino acid pharmacology in neocortical slices: evidence for bimolecular actions from an extension of the Hill and Gaddum‐Schild equations , 1988, British journal of pharmacology.
[81] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[82] D. Dickson. Neuropathology of Parkinson disease. , 2018, Parkinsonism & related disorders.
[83] E. Tolosa,et al. A Novel p.Glu298Lys Mutation in the ACMSD Gene in Sporadic Parkinson's Disease. , 2017, Journal of Parkinson's disease.
[84] A. Massey,et al. Alpha-Synuclein, a Novel Viral Restriction Factor Hiding in Plain Sight. , 2016, DNA and cell biology.
[85] F. Blandini,et al. A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease , 2013, Journal of Neural Transmission.
[86] R. Schwarcz,et al. Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry , 2007, Glia.
[87] D. S. Albers,et al. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism , 2005, Amino Acids.
[88] B. Brew,et al. Expression of the kynurenine pathway enzymes in human microglia and macrophages. , 2003, Advances in experimental medicine and biology.
[89] Y. Egashira,et al. Identification and expression of a cDNA encoding human alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase (ACMSD). A key enzyme for the tryptophan-niacine pathway and "quinolinate hypothesis". , 2002, The Journal of biological chemistry.
[90] P. Riederer,et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. , 1994, Neuroscience letters.